Advanced search
Publication Cover
Pathology Volume 33, 2001 - Issue 1
Submit an article Journal homepage
15
Views
1
CrossRef citations to date
0
Altmetric
Research Article

THE SMAD PROTEINS AND TGFβ SIGNALLING: UNCOVERING A PATHWAY CRITICAL IN CANCER

Heather M. Rooke, Kathryn E. Crosier Division of Molecular Medicine, School of Medicine, University of Auckland, New Zealand
Pages 73-84 | Published online: 06 Jul 2009

  • Kingsley DM. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 1994; 8: 133-46.
  • Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB. New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci USA 1981; 78: 5339-43.
  • Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol 1990; 6: 597-641.
  • Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 1995; 121: 1845-54.
  • Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, et al Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992; 359: 693-9.
  • Kulkarni AB, Huh CG, Decker D, Geiser A, Lyght M, Flanders KC, et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993; 90: 770-4.
  • Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, Friedman R, Boivin GP, et al TGFbeta2 knockout mice have multiple developmental defects that are non- overlapping with other TGFbeta knockout phenotypes. Development 1997; 124: 2659-70.
  • Proetzel G, Pawlowski SA, Wiles MV, Yin M, Boivin GP, Howles PN, et al. Transforming growth factor-beta 3 is required for secondary palate fusion. Nat Genet 1995; 11: 409-14.
  • Kaartinen V, Voncken JW, Shuler C, Warburton D, Bu D, Heisterkamp N, et al. Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat Genet 1995; 11: 415-21.
  • Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R. TGFbeta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 1990; 63: 515-24.
  • Laiho M, DeCaprio JA, Ludlow JW, Livingston DM, Massague J. Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation. Cell 1990; 62: 175-85.
  • Keller JR, McNiece IK, Sill KT, Ellingsworth LR, Quesenberry PJ, Sing GK, et al. Transforming growth factor ß directly regulates primitive murine hematopoietic cell proliferation. Blood 1990; 75: 596-602.
  • Sherr CJ. Mammalian Gl cyclins. Cell 1993; 73: 1059-65.
  • Hannon GJ, Beach D. p25INK4B is a potential effector of TGF-betainduced cell cycle arrest. Nature 1994; 371: 257-61.
  • Reynisdottir I, Polyak K, lavarone A, Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 1995; 9: 1831-45.
  • Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of Gl-phase progression. Genes Dev 1999; 13: 1501-12.
  • Derynck R. TGF-beta-receptor-mediated signaling. Trends Biochem Set 1994; 19: 548-53.
  • Ventura F, Doody J, Liu F, Wrana JL, Massague J. Reconstitution and transphosphorylation of TGF-beta receptor complexes. EMBO J 1994; 13: 5581-9.
  • Brown CB, Boyer AS, Runyan RB, Barnett JV. Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart. Science 1999; 283: 2080-2.
  • Arthur HM, Ure J, Smith AJ, Renforth G, Wilson DI, Torsney E, et al. Endoglin, an ancillary TGFbeta receptor is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol 2000; 217: 42-53.
  • McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994; 8: 345-51.
  • Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 1990; 110: 1361-7.
  • Abe M, Oda N, Sato Y. Cell-associated activation of latent transforming growth factor-beta by calpain. / Cell Physiol 1998; 174: 186-93.
  • Sekelsky JJ, Newfeld SJ, Raftery LA, Chartoff EH, Gelbart WM. Genetic characterisation and cloning of Mothers Against dpp, a gene required for decapentaplegic function in Drosophila melanogaster. Genetics 1995; 139: 1347-58.
  • Savage C, Das P, Finelli AL, Townsend SR, Sun CY, Baird SE, et al. Caenorhabditis elegans genes sma-2, sma-3, and sma-4 define a conserved family of transforming growth factor beta pathway components. Proc Natl Acad Sci USA 1996; 93: 790-4.
  • Derynck D, Gelbart WM, Harland RM, Heldin C-H, Kern SE, Massague J, et al. Nomenclature: vertebrate mediators of TGFß family signals. Cell 1996; 87: 173.
  • Hoodless PA, Haerry T, Abdollah S, Stapleton M, O'Connor MB, Attisano L, et al. MADRl, a MAD-related protein that functions in BMP2 signaling pathways. Cell 1996; 85: 489-500.
  • Liu F, Hata A, Baker JC, Doody J, Carcamo J, Harland RM, et al A human Mad protein acting as a BMP-regulated transcriptional activator. Nature 1996; 381: 620-3.
  • Baker JC, Harland RM. A novel mesoderm inducer, Madr2, functions in the activin signal transduction pathway. Genes Dev 1996; 10: 1880-9.
  • Bruno E, Horrigan SK, Van Den Berg D, Rozler E, Fitting PR, Moss ST, et al The Smad5 gene is involved in the intracellular signaling pathways that mediate the inhibitory effects of transforming growth factor-beta on human hematopoiesis. Blood 1998; 91: 1917-23.
  • Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, et al MADR2 maps to 18q21 and encodes a TGFbeta-regulated MADrelated protein that is functionally mutated in colorectal carcinoma. Cell 1996; 86: 543-52.
  • Chen YG, Hata A, Lo RS, Wotton D, Shi Y, Pavletich N, et al Determinants of specificity in TGF-beta signal transduction. Genes Dev 1998; 12: 2144-52.
  • Hahn SA, Schutte M, Hbque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350-3.
  • Shi Y, Hata A, Lo RS, Massague J, Pavletich NP. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature 1997; 388: 87-93.
  • Hayashi H, Abdollah S, Qiu Y, Cai J, Xu Y-Y, Grinnell BW, et al. The MAD-related protein Smad7 associates with the TGFß receptor and functions as an antagonist of TGFß signaling. Cell 1997; 89: 1165-73.
  • Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M, et al Smad6 inhibits signalling by the TGF-beta superfamily. Nature 1997; 389: 622-6.
  • Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, et al Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 1997; 389: 631-5.
  • Topper JN, Cai J, Qiu Y, Anderson KR, Xu YY, Deeds JD, et al. Vascular MADs: two novel MAD-related genes selectively inducible by flow in human vascular endothelium. Proc Natl Acad Sci USA 1997; 94: 9314-9.
  • Tsuneizumi K, Nakayama T, Kamoshida Y, Kornberg TB, Christian JL, Tabata T. Daughters against dpp modulates dpp organizing activity in Drosophila wing development. Nature 1997; 389: 627-31.
  • Souchelnytskyi S, Nakayama T, Nakao A, Moren A, Heldin CH, Christian JL, et al. Physical and functional interaction of murine and Xenopus Srnad? with bone morphogenetic protein receptors and transforming growth factor- beta receptors. J Biol Chem 1998; 273: 25364-70.
  • Afrakhte M, Moren A, Jossan S, Itoh S, Sampath K, Westermark B, et al Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members. Biochem Biophys Res Commun 1998; 249: 505-11.
  • Hata A, Lagna G, Massague J, Hemmati-Brivanlou A. Smado inhibits BMP/Smadl signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev 1998; 12: 186-97.
  • Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 1999; 397: 710-3.
  • Tsukazald T, Chiang TA, Davison AF, Attisano L, Wrana JL. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell 1998; 95: 779-91.
  • Hata A, Lo RS, Wotton D, Lagna G, Massague J. Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4. Nature 1997; 388: 82-7.
  • Shi Y, Wang YF, Jayaraman L, Yang H, Massague J, Pavletich NP. Crystal structure of a Smad MHl domain bound to DNA: insights on DNA binding in TGF-beta signaling. Cell 1998; 94: 585-94.
  • Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1gene. EMBO J 1998; 17: 3091-100.
  • Chen X, Rubock MJ, Whitman M. A transcriptional partner for MAD proteins in TGF-ß signalling. Nature 1996; 383: 691-6.
  • Chen X, Weisberg E, Fridmacher V, Watanabe M, Naco G, Whitman M. Smad4 and FAST-1 in the assembly of activin-responsive factor. Nature 1997; 389: 85-9.
  • Zhang Y, Feng XH, Derynck R. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription. Nature 1998; 394: 909-13.
  • Liberati NT, Datto MB, Frederick JP, Shen X, Wong C, RougierChapman EM, et al. Smads bind directly to the Jun family of AP-I transcription factors. Proc Natl Acad Sei USA 1999; 96: 4844-9.
  • Pennisi E. Opening the way to gene activity. Science 1997; 275: 155-7.
  • Feng XH, Zhang Y, Wu RY, Derynck R. The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation. Genes Dev 1998; 12: 2153-63.
  • Janknecht R, Wells NJ, Hunter T. TGF-beta-stimulated cooperation of smad proteins with the coactivators CBP/p300. Genes Dev 1998; 12: 2114-9.
  • Pouponnot C, Jayaraman L, Massague J. Physical and functional interaction of SMADs and p300/CBP. J Biol Chem 1998; 273: 22865-8.
  • Wotton D, Lo RS, Lee S, Massague J. A Smad transcriptional corepressor. Cell 1999; 97: 29-39.
  • Luo K, Stroschein SL, Wang W, Chen D, Martens E, Zhou S, Zhou Q. The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. Genes Dev 1999; 13: 2196-206.
  • Stroschein SL, Wang W, Zhou S, Zhou Q, Luo K. Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science 1999; 286: 771-4.
  • Sun Y, Liu X, Eaton EN, Lane WS, Lodish HF, Weinberg RA. Interaction of the Ski oncoprotein with Smad3 regulates TGF-beta signaling. MoI Cell 1999; 4: 499-509.
  • Sun Y, Liu X, Ng-Eaton E, Lodish HF, Weinberg RA. SnoN and Ski protooncoproteins are rapidly degraded in response to transforming growth factor beta signaling. Proc Natl Acad Sci USA 1999; 96: 12442-7.
  • Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 1995; 270: 2008-11.
  • Garrington TP, Johnson GL. Organization and regulation of mitogenactivated protein kinase signaling pathways. Curr Opin Cell Biol 1999; 11:211-8.
  • Sano Y, Harada J, Tashiro S, Gotoh-Mandeville R, Maekawa T, Ishii S. ATF-2 is a common nuclear target of Smad and TAKl pathways in transforming growth factor-beta signaling. J Biol Chem 1999; 274: 8949-57.
  • Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K. The kinase TAKl can actiate the NIK-I kappaB as well as the MAP kinase cascade in the IL-I signalling pathway. Nature 1999; 398: 252-6.
  • Wang T, Donahoe PK, Zervos AS. Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12. Science 1994; 265: 674-6.
  • Wang T, Li BY, Danielson PD, Shah PC, Rockwell S, Lechleider RJ, Martin J, Manganaro T, Donahoe PK. The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors. Cell 1996; 86: 435-44.
  • Huse M, Chen YG, Massague J, Kuriyan J. Crystal structure of the cytoplasmic domain of the type ITGF beta receptor in complex with FKBP12. Cell 1999; 96: 425-36.
  • Kretzschmar M, Doody J, Massague J. Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smadl. Nature 1997; 389: 618-22.
  • Kretzschmar M, Doody J, Timokhina I, Massague J. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev 1999; 13: 804-16.
  • Yanagisawa J, Yanagi Y, Masuhiro Y, Suzawa M, Watanabe M, Kashiwagi K, et al. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999; 283: 1317-21.
  • Yanagi Y, Suzawa M, Kawabata M, Miyazono K, Yanagisawa J, Kato S. Positive and negative modulation of vitamin D receptor function by transforming growth factor-beta signaling through smad proteins. J Biol Chem 1999; 274: 12971-4.
  • Brown JD, DiChiara MR, Andersen KR, Gimbrone MA Jr, Topper JN. MEKK-I, a component of the stress (stress-activated protein kinase/c-Jun N-terminal kinase) pathway, can selectively activate Smad2-mediated transcriptional activation in endothelial cells. J Biol Chem 1999; 274: 8797-805.
  • Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995; 268: 1336-8.
  • Myeroff LL, Parsons R, Kim SJ, Hedrick L, Cho KR, Orth K, et al. A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 1995; 55: 5545-7.
  • Imai Y, Tsurutani N, Oda H, Inoue T, Ishikawa T. Genetic instability and mutation of the TGF-beta-receptor-II gene in ampullary carcinomas. Int J Cancer 1998; 76: 407-11.
  • Izumoto S, Arita N, Ohnishi T, Hiraga S, Taki T, Tomita N, et al Microsatellite instability and mutated type II transforming growth factor-beta receptor gene in gliomas. Cancer Lett 1997; 112: 251-6.
  • Gartenhaus R, Johns MM III, Wang P, Rai K, Sidransky D. Mutator phenotype in a subset of chronic lymphocytic leukemia. Blood 1996; 87: 38-41.
  • Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD, et al. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res 1999; 59: 320-4.
  • Parsons R, Myeroff LL, Liu B, Willson JK, Markowitz SD, Kinder KW, et al. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res 1995; 55: 5548-50.
  • Garrigue-Antar L, Munoz-Antonia T, Antonia SJ, Gesmonde J, Vellucci VF, Reiss M. Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells. Cancer Res 1995; 55: 3982-7.
  • Knaus PI, Lindemann D, DeCoteau JF, Perlman R, Yankelev H, HiIIe M, et al. A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma. MoI Cell Biol 1996; 16: 3480-9.
  • Chen T, Carter D, Garrigue-Antar L, Reiss M. Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer. Cancer Res 1998; 58: 4805-10.
  • Duff EK, Clarke AR. Smad4 (DPC4)-a potent tumour suppressor? Br J Cancer 1998; 78: 1615-9.
  • Riggins GJ, Kinder KW, Vogelstein B, Thiagalingam S. Frequency of Smad gene mutations in human cancers. Cancer Res 1997; 57: 2578-80.
  • Takagi Y, Koumura H, Futamura M, Aoki S, Ymaguchi K, Kida H, et al Somatic alterations of the SMAD-2 gene in human colorectal cancers. Br J Cancer 1998; 78: 1152-5.
  • Zhu Y, Richardson JA, Parada LF, Graff JM. Smad3 mutant mice develop metastatic colorectal cancer. Cell 1998; 94: 703-14.
  • Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE. Genetic alterations of the transforming growth factor betareceptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 1998; 58: 5329-32.
  • Kurokawa M, Mitani K, Imai Y, Ogawa S, Yazaki Y, Hirai H. The t(3;21) fusion product, AML/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells. Blood 1998; 92: 4003-12.
  • Akhurst RJ, Balmain A. Genetic events and the role of TGF beta in epithelial tumour progression. J Pathol 1999; 187: 82-90.
  • Rooke HM, Vitas MR, Crosier PS, Crosier KE. The TGF-beta type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression. Leukemia 1999; 13: 535-41.
  • Capocasale RJ, Lamb RJ, Vonderheid EC, Fox FE, Rook AH, Nowell PC, et al. Reduced surface expression of transforming growth factor receptor ß type II in mitogen-activated T cells from Sézary patients. Proc NallAcad Sei USA 1995; 92: 5501-5.
  • Kadin ME, Cavaille-Coll MW, Gertz R, Massagué J, Cheifetz S, George D. Loss of receptors for transforming growth factor ß in human T-cell malignancies. Proc Natl Acad Sci USA 1994; 91: 6002-6.
  • Matsushita M, Matsuzald K, Date M, Watanabe T, Shibano K, Nakagawa T, et al. Down-regulation of TGF-beta receptors in human colorectal cancer: implications for cancer development. Br J Cancer 1999; 80: 194-205.
  • Oft M, Heider KH, Beug H. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 1998; 8: 1243-52.
  • Bubb VJ, Curtis LJ, Cunningham C, Dunlop MG, Carothers AD, Morris RG, et al. Microsatellite instability and the role of HMSH2 in sporadic colorectalcancer. Oncogene 1996; 12: 2641-9.
  • Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al., Cyclosporine induces cancer progression by a cellautonomous mechanism. Nature 1999; 397: 530-4.
  • Steiner MS, Zhou ZZ, Tonb DC, Barrack ER. Expression of transforming growth factor-beta 1 in prostate cancer. Endocrinology 1994; 135: 2240-7.
  • Kimchi A, Wang XF, Weinberg RA, Cheifetz S, Massague J. Absence of TGF-beta receptors and growth inhibitory responses in retinoblastoma cells. Science 1988; 240: 196-9.
  • Hougaard S, Norgaard P, Abrahamsen N, Moses HL, SpangThomsen M, Skovgaard Poulsen H. Inactivation of the transforming growth factor beta type II receptor in human small cell lung cancer cell lines. Br J Cancer 1999; 79: 1005-11.
  • Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, et al. DPC4 gene in various tumor types. Cancer Res 1996; 56: 2527-30.
  • Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996; 13: 343-6.
  • Linardopoulos S, Street AJ, Quelle DE, Parry D, Peters G, Sherr CJ, et al. Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors. Cancer Res 1995; 55: 5168-72.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.